Table 2.

Characteristics of studies used to derive signatures for risk profiling on tuberculosis datasets.

	Tissue	Sequencing platform	Cohort	Severity	Eligible signatures
Wilk et al.26	PBMCs	Seq-Well	7 patients hospitalized with confirmed COVID-19 (all male, aged 20–80+ yrs.), 6 healthy controls	3 COVID-19 patients were on ventilation and diagnosed with ARDS; 4 were less severely ill patients. Samples collected 2–16 days following symptom onset	4
Huang et al.27	PBMCs	10X Chromium	8 active disease patients, 2 cured patients, 3 healthy controls, and non-COVID-19 patients	Active disease patients: 1 critical case, 1 severe case, 6 moderate cases. Non-COVID-19 patients: 1 case of influenza A, 1 case of acute pharyngitis, and 1 case of cerebral infarction	1
Wen et al.20	PBMCs	10X Chromium	10 recovering patients (5 male, 5 female, aged 40–70 yrs.), plus healthy controls	5 early-recovery stage (ERS) and 5 late-recovery stage (LRS) patients, classified by days between blood sampling date and negative qPCR	5
Liao et al.13	BALF	10X Chromium	6 COVID-19 patients (5 male, 1 female, median age: 49.5), 8 previously reported healthy lung controls	3 severe, 3 mild	6
Xiong et al.x	BALF and PBMCs	MGISEQ-2000	3 COVID-19 patients and 3 healthy controls	No severity information provided	2
Hadjadj et al.22	Whole blood	nanoString nCounter	50 COVID-19 patients with a spectrum of disease severity	15 mild/moderate, 17 severe, and 18 critical	5
Wei et al.21	PBMCs	10X Chromium	4 COVID-19 patients	Patients sampled before, during, and after ICU care	4
Silvin et al.28	Whole blood	10X Chromium	3 COVID-19 patients and 3 healthy controls	1 mild, 2 severe patients sampled at day 0 and day 10	3
Arunachalam et al.23	PBMCs	10X Chromium	7 COVID-19 patients and 5 healthy controls	No severity information provided for scRNA-seq samples	5
Dunning et al.9	Whole blood	Illumina GenomeStudio	131 influenza patients, 155 healthy controls	Not applicable	1